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ministrative data provides an opportunity to examine
this use in the general population. OBJECTIVES: The
study purpose was to investigate how sedative/hypnotic
drugs are used in an ambulatory population. METH-
ODS: A retrospective analysis of prescription claims from
an integrated database. Persons with at least one pre-
scription for a nonbarbiturate sedative/hypnotic in a 36-
month sampling frame (1/1/95–12/31/97) were included.
Sedative/hypnotic agents included: estazolam, ethchlor-
vynol, flurazepam, glutethimide, quazepam, temazepam,
triazolam, and zolpidem. RESULTS: 55,086 persons had
at least one claim for the drugs of interest. 58% were fe-
male, the average age was 62 years  14.5 years, with a
range of 3–104 years. 58% of those identified were 60
years of age. Women were only slightly older than men
(62.1 years compared to 61.8 years). The most com-
monly used agent during the study timeframe was zolpi-
dem (a short-acting agent) with 58% of identified sub-
jects having at least one claim. This was followed by
temazepam (an intermediate acting agent) used by 36%
of persons identified. 53% of persons using zolpidem and
36% of persons using temazepam were 60 years of age.
27% of persons identified had claims evidence suggestive
of single, one time acquisition of a sedative/hypnotic
agent during a 12-month period of time. CONCLUSION:
The majority of persons in this ambulatory population
used short or intermediate acting sedative/hypnotics, for
extended use. A large number of patients 60 years of
age rely on benzodiazepine-based agents (temazepam)
that can produce daytime sedation which may decrease
daytime functioning.
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OBJECTIVE: This study documented the relationship be-
tween antipsychotic drug use patterns and direct health
care costs for community-dwelling patients with schizo-
phrenia in four state Medicaid programs. METHODS: A
one-year treatment period was defined for each patient
(N  18,090). Logistic regression models were used to
investigate the predictors of not having used any medica-
tion, delaying therapy, changes in therapy, and complet-
ing one year of continuous therapy. Regression analyses
were used to estimate the impact of these patterns of an-
tipsychotic drug use on direct health care costs. RESULTS:
The average annual total direct cost for community-
dwelling patients with schizophrenia was $13,650 (N 
18,090). Approximately 24% of patients did not use any
antipsychotic drug for at least one year and consumed
significantly fewer services ($3,200). Delaying antipsy-
chotic therapy (18%) was associated with an increase in
total cost of care of $3,936 (P  0.0001). Patients who
switched or augmented their initial therapy (41%) were
also found to experience higher total cost of care
($4,019, P  0.0001). Continuous antipsychotic therapy
(18%) was associated with significant shifts in the type of
care consumed ($1,337 in hospital costs; $652 in nurs-
ing home costs; $1,237 in ambulatory services and $939
in other services), leaving total cost unchanged. CONCLU-
SIONS: A significant proportion of patients with schizo-
phrenia treated with traditional antipsychotic medica-
tions did not display drug utilization patterns consistent
with successful drug therapy. Suboptimal drug use pat-
terns were associated with increased direct healthcare costs.
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OBJECTIVE: This study examined medical resource con-
sumption by patients with chronic and breakthrough
pain (BTP) who were using transdermally-delivered fent-
anyl for the management of chronic pain. Patients were
participants in a broader survey designed to collect clini-
cal and economic information regarding their pain.
METHODS: Surveys were administered to cancer and
non-cancer patients with chronic and BTP to assess med-
ical resources consumed in the past 30 days. Patients
were identified from investigator practices and asked to
participate in an interview. Data were collected for physi-
cian contacts, Emergency Department (ED) visits, hospi-
talizations, prescription use, patient work loss, and care-
giver time and work loss. RESULTS: 102 patients were
enrolled at the time of this analysis; 95 (93%) completed
the survey. Forty (42%) were men and 55 (58%) were
women. 42% reported calling and 44% visited their phy-
sician’s office, averaging 1.05 telephone calls and 0.68
visits specifically because of BTP. Patients averaged 2.55
prescriptions for pain control during the period. Twelve
patients (13%) reported 16 ED visits, and 11 patients
(12%) reported 13 hospitalizations. Only 20 of the 95
patients (21%) were working in a paid job. Of these,
70% (14/20) reported lost work, an average of 36.9
hours during the prior 30 days, due to pain. Nearly 83%
of patients reported having someone help with their per-
sonal and/or medical care. Caregivers spent an average of
77 hours helping patients. Twenty-four patients (25%)
reported an average of 24 hours of caregiver work loss as
a result. CONCLUSIONS: The magnitude of medical re-
source consumption due to pain is notable, and lost work
